Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable
about
Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A SurveyDifferent PD-MCI criteria and risk of dementia in Parkinson's disease: 4-year longitudinal studyThe Everyday Cognition Scale in Parkinson's disease.Diminished EEG habituation to novel events effectively classifies Parkinson's patients.Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health.
P2860
Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Therapeutic development paths ...... ort of a regulatory roundtable
@ast
Therapeutic development paths ...... ort of a regulatory roundtable
@en
type
label
Therapeutic development paths ...... ort of a regulatory roundtable
@ast
Therapeutic development paths ...... ort of a regulatory roundtable
@en
prefLabel
Therapeutic development paths ...... ort of a regulatory roundtable
@ast
Therapeutic development paths ...... ort of a regulatory roundtable
@en
P2093
P2860
P50
P356
P1476
Therapeutic development paths ...... ort of a regulatory roundtable
@en
P2093
Daniel Weintraub
Glenn Stebbins
Jamie Eberling
Jennifer G Goldman
Lona Vincent
P2860
P304
P356
10.3233/JPD-140385
P577
2014-01-01T00:00:00Z